Trials / Conditions / Unresectable Pancreatic Carcinoma

Unresectable Pancreatic Carcinoma

19 registered clinical trials studyying Unresectable Pancreatic Carcinoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advan NCT05411094	National Cancer Institute (NCI)	Phase 1
Recruiting	Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors NCT05053971	National Cancer Institute (NCI)	Phase 1 / Phase 2
Recruiting	A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep an NCT07280377	Oncolytics Biotech	Phase 1 / Phase 2
Active Not Recruiting	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fa NCT04673448	University of Washington	Phase 1
Recruiting	Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer NCT04158635	City of Hope Medical Center	Phase 1
Withdrawn	Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumor NCT03925428	National Cancer Institute (NCI)	Phase 1
Completed	Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer NCT03819088	Emory University	N/A
Active Not Recruiting	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer NCT03825289	University of Utah	Phase 1
Active Not Recruiting	Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder C NCT03257761	University of Southern California	Phase 1
Active Not Recruiting	TAS102 in Combination With NAL-IRI in Advanced GI Cancers NCT03368963	Emory University	Phase 1 / Phase 2
Completed	Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer NCT03095781	Emory University	Phase 1
Completed	Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors o NCT03033225	Mayo Clinic	Phase 2
Completed	Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients NCT02767557	Herlev Hospital	Phase 2
Completed	Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic NCT02896907	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	EARLY_Phase 1
Active Not Recruiting	A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors NCT02498613	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Rem NCT02595931	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, an NCT02336087	City of Hope Medical Center	Phase 1
Completed	Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhi NCT02194829	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surg NCT01783171	National Cancer Institute (NCI)	Phase 1